NewsBenzingaNervGen称FDA授予NVG-291突破性疗法认定,用于治疗慢性创伤性颈髓运动不完全性脊髓损伤 NervGen称FDA授予NVG-291突破性疗法认定,用于治疗慢性创伤性颈髓运动不完全性脊髓损伤 Benzinga 2026.11.12 12:21 (GMT+0) Open on Benzinga Other news Dan Ives Says ‘Clearly Jensen Wants to Come Back as CEO’, Sees Potential Special Shareholder Meeting Telsey Advisory Group Maintains Market Perform on Kohl's, Raises Price Target to $25 Red Cat Q3 Revenue Contracts 42% in Q3, Analysts Cut Price Targets Citigroup Maintains Neutral on Petrobras Brasileiro, Lowers Price Target to $18.5 Nike Executive Says 2028 Will Be ‘A Challenging Year Financially’; Co. Expects Adjusted EPS To Decline Modestly In Fiscal 2028 From Fiscal 2027 Levels Lake Street Maintains Buy on Glass House Brands, Lowers Price Target to $3
Nike Executive Says 2028 Will Be ‘A Challenging Year Financially’; Co. Expects Adjusted EPS To Decline Modestly In Fiscal 2028 From Fiscal 2027 Levels